Background. Whether echinocandins could be used to treat candidemia of a urinary tract source (CUTS) is unknown. We aimed to provide current epidemiological information of CUTS and to compare echinocandin to fluconazole treatment on CUTS outcomes.
Candidemia is a common cause of bloodstream infection worldwide [1] [2] [3] [4] and is still associated with significant morbidity and mortality [5] [6] [7] . Most candidemia episodes are considered to arise from an endogenous source or, less often, through the colonization of vascular catheters via the skin [8, 9] . However, some patients with urinary colonization and obstructive urological disorders may develop candidemia from an ascending infection beginning in the lower urinary tract [10] [11] [12] . Nowadays, several matters have arisen regarding the management of candidemia of a urinary tract source (CUTS).
Current guidelines recommend fluconazole or amphotericin B deoxycholate to treat Candida infections from the urinary tract due to the ability of these antifungal drugs to achieve adequate urinary concentrations [13, 14] . However, recent epidemiological studies have raised concerns about the increasing prevalence of Candida species nonsusceptible to fluconazole [15] [16] [17] [18] , although specific microbiological data of patients with CUTS are lacking. Moreover, patients with Candida infections from a urinary source are often elderly and have severe comorbidities, including impaired renal function, which precludes the use of amphotericin B. Finally, the usefulness of echinocandins to treat episodes of CUTS is controversial given its low concentration reached in urine [19] , and clinical data supporting the use of such drugs in this setting are scarce.
Our primary aim was to compare echinocandin to fluconazole treatment in patients with CUTS and, specifically, to assess whether echinocandins were associated with negative outcomes. We also provide current information on the epidemiology of CUTS from a large cohort of patients with candidemia.
METHODS

Setting, Patients, and Study Design
Using data from an extensive multicenter cohort of patients with candidemia, we performed a retrospective study of all episodes of CUTS occurring in hospitalized adult patients between January 2006 and December 2015. The study was conducted in 9 tertiary teaching institutions in 2 countries: 8 from Spain and 1 from Argentina. The following information was collected from medical records: demographic characteristics, comorbidities, clinical features, causative species, antifungal therapy, and outcomes.
General Definitions
Candidemia was defined as the presence of at least 1 positive blood culture for Candida species in a patient with clinical signs and symptoms of sepsis. Only the first episode of candidemia was analyzed per patient. We defined CUTS as an episode of candidemia occurring in a patient with urinary tract symptoms, with concomitant candiduria due to the same Candida species and with significant urological comorbidity (obstruction or manipulation of the urinary tract). Possible CUTS episodes were reviewed by 3 study investigators who were part of a 9-member clinical review panel (G. C., C. G.-V., M. P.-A., A. V., Y. M., M. F.-R., E. G.-B., M. J. B.-V., and A. M.). All members of the clinical review panel were infectious disease specialists and had extensive clinical experience treating candidemia. The reviewers were asked to check the microbiologic results and the baseline urologic comorbidity, and to exclude other potential source of candidemia.
A diagnosis of septic shock was made when the systolic blood pressure was <90 mm Hg and there was clinical evidence of peripheral hypoperfusion and/or the need for vasopressors. Neutropenia was defined as a granulocyte count <500 cells/µL. Initial antifungal therapy was considered to be appropriate when the Candida species isolate showed in vitro susceptibility to the antifungal drug administered. Acute renal failure was defined as an increase in serum creatinine concentration of 44.2 μmol/L if the baseline level was <221 μmol/L, an increase of >20% if the baseline level was >221 μmol/L, or the need for dialysis at the onset of candidemia [20] . A urologic procedure was defined as a urinary catheter exchange or any surgical, percutaneous, or endoscopic drainage of the urinary tract and it was considered as a source control procedure if it was performed within 48-72 hours of candidemia onset (early urologic procedure).
Definitions of Outcomes
For the purpose of the study, we assessed the outcomes on patients treated with echinocandin compared with those treated with fluconazole. To be included in the evaluation of outcomes, patients had to receive at least 2 consecutive days of therapy with either fluconazole or echinocandin as initial antifungal therapy after blood culture collection (except for patients who died within the first 48 hours, who had to receive at least 1 complete day of therapy for inclusion). Initial antifungal therapy was considered to be appropriate when the Candida isolate showed in vitro susceptibility to the antifungal drug administered. For episodes caused by Candida glabrata initially treated with fluconazole, antifungal therapy was considered to be appropriate when the dose to minimum inhibitory concentration (MIC) ratio of fluconazole was ≥25 [21, 22] . The primary outcome of our study was clinical failure, defined as a composite endpoint that included 7-day mortality and/or the presence of persistent candidemia. Persistent candidemia was defined as persistently positive blood cultures after ≥72 hours of treatment initiation [23] . Early and 30-day mortality were defined as death from any cause within 7 and 30 days, respectively, of the onset of candidemia.
Microbiological Studies
Two sets of 2 blood samples were collected from patients with suspected bloodstream infection. The blood samples were processed using a BACTEC 9240 system (Becton-Dickinson, Franklin Lakes, New Jersey) or BacTAlert (bioMérieux SA, Marcy L'Etoile, France), with an incubation period of 5 days. If yeast cells were observed after microscopic Gram stain examination, blood bottles were subcultured onto Sabouraud agar plates (BD BBL Stacker Plates, Heidelberg, Germany) and chromogenic media (ChromAgar, bioMérieux SA, Paris, France). Yeast isolates were identified by conventional methods. Candida isolates were processed and stored at participating hospitals. The antifungal susceptibility of the isolates was classified in accordance with the Clinical and Laboratory Standards Institute M27-S3 document [24] . In vitro antifungal activity was studied by applying a commercial microdilution method (YeastOne Sensititre, TREK Diagnostic Systems, Independence, Ohio) or an Etest (bioMérieux SA, Marcy L'Etoile, France), following the manufacturer's instructions. The fluconazole MIC was defined as the lowest drug concentration that inhibited 50% of growth compared with the growth control after 24 hours of incubation at 35°C for all Candida species, except for C. glabrata, which was determined after 48 hours to prevent misclassification bias among the isolates [25] . Of note, those Candida species isolates with a minimum inhibitory concentration (MIC) ≥4 mg/L to fluconazole were considered nonsusceptible to fluconazole, with the exception of C. glabrata, which was considered susceptible dose-dependent to fluconazole when the MIC value was ≤32 mg/L and Candida krusei, which was considered nonsusceptible to fluconazole regardless of their MIC value. Quality controls were performed in each center using Candida parapsilosis ATCC 22019 and C. krusei ATCC 6258.
Statistical Analysis
Quantitative variables are reported as median with interquartile range (IQR); categorical variables are reported as absolute numbers and percentages. To detect significant differences between groups, we used the χ 2 
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RESULTS
Demographics and Epidemiology
In total, 2176 candidemia episodes occurred within the study period, of which 128 (5.88%) were CUTS; 83 cases (64.8%)
were in men and 77 (60.2%) were in patients >70 years of age. 
Therapeutic Approaches and Outcomes
Fluconazole was the most frequently drug administered (n = 88 [68.8%]), whereas echinocandins were used in 35 patients (27.3%). One patient received voriconazole (0.8%). Four patients (3.1%) received no antifungal treatment. An early urologic procedure was performed in more than half of the patients (n = 65 [50.8%]). The early mortality, clinical failure, and 30-day mortality percentages were 6.3%, 20.3%, and 14.8%, respectively. Table 1 summarizes the demographic and clinical characteristics of the patients treated for CUTS. Patients treated with echinocandins had more frequently received chemotherapy (17.1% compared with 2.3%; P = .007), corticosteroids (40% compared with 15.9%; P = .005), and immunosuppressive drugs (25.7% compared with 4.5%; P = .002) within the month prior to infection. The presence of fever, severe sepsis/septic shock, acute renal failure, and ICU requirement at candidemia onset were similar between the groups, regardless of initial therapy. Table 2 details the microbiologic results, therapy, and outcomes of both groups. Patients treated with echinocandins had significantly fewer C. albicans but more C. glabrata isolations. The appropriation on initial antifungal therapy was similar between groups. Fluconazole-treated patients underwent urologic procedures more often (31.4% vs 60.2%; P = .003). Univariate analysis did not show any differences in outcomes according to initial therapy with echinocandins or fluconazole.
Demographics, Microbiology, and Outcomes by Echinocandin or Fluconazole Treatment
Predictors of Clinical Failure in Patients Treated With Echinocandins or Fluconazole
In the multivariate analysis (Table 3) , only acute renal failure at onset of CUTS was an independent predictor of clinical failure (adjusted odds ratio [AOR], 3.01; 95% confidence interval [CI], 1.01-8.91; P = .047). By contrast, performing an early urologic procedure appeared to be a protective measure (AOR, 0.08; 95% CI, .02-.31; P < .001). Neither univariate nor multivariate analysis showed that the initial use of echinocandin therapy affected the risk of clinical failure. This finding was also unaffected by incorporating the propensity score for receiving echinocandins into the model. The goodness of fit of the propensity score derivation model was assessed by the Hosmer-Lemeshow test (P = .860), and the discriminatory power of the score, as evaluated by the area under the receiver operating characteristic curve, was 0.72 (95% CI, .61-.82), showing a good ability to predict echinocandin use. The consistency of this result was confirmed by repeating the propensity score analyses by 1:1 matching with replacement and a caliper of 0.25, and by quintile stratification (data not shown).
DISCUSSION
In this research, we focused on whether echinocandins were safe and efficacious in patients with CUTS. Our study highlights the pertinence of resolving this issue, because we found that more than half of the patients with CUTS were elderly (≥70 years old), many had chronic renal disease, and a high proportion of the infections were caused by strains less susceptible to fluconazole. Consequently, amphotericin B use might give unacceptable side effects while fluconazole use may be limited by antifungal resistance.
The successful use of caspofungin and micafungin for the treatment of Candida cystitis [28, 29] , candiduria [30] , and CUTS caused by C. albicans [31] has been documented in a few reports. It is known that echinocandins achieve poor urinary concentrations, but that their accumulation in renal parenchyma is high [19] . This fact might play a role in limiting the translocation of infection from urine to blood, and it could explain the favorable outcomes observed in isolated case reports [31, 32] . Abbreviations: IQR, interquartile range. a One patient in the fluconazole group had a mixed albicans-glabrata candidemia.
b Fluconazole susceptibility was determined in 120 strains.
c Echinocandin susceptibility was determined in 85 strains. There were no isolates resistant both to fluconazole and to echinocandins. d The insertion, change, or manipulation of a urinary catheter accounted for 23 urologic procedures (36%) and was similarly distributed in both groups (n = 5/14% vs 18/20%; P = not significant). Moreover, due to the low urinary protein levels, it is tempting to speculate that a greater amount of echinocandins in urine could be free and bioactive. In line with this, some researchers [29] have found that a pharmacokinetic/pharmacodynamic target of Cmax/MIC >4 of micafungin in urine was useful to predict success in most patients with symptomatic urinary tract infections caused by Candida species. We did not find any differences in the clinical failure rates between patients treated for CUTS with echinocandins and those treated with fluconazole.
Although this was not a randomized study and definitive conclusions cannot be drawn, we have added further information supporting the use of echinocandins in patients with CUTS. These drugs actually could represent the last resort for elderly patients with comorbidities and CUTS caused by azole-resistant strains, mainly for patients in whom an early drainage of the urinary tract is possible.
To our knowledge, a cohort of patients with CUTS has only previously been described in 1 observational study [10] . That study included a low number of patients (26 cases with CUTS from a total cohort of 249 episodes of candidemia [10.4%] ) and was performed in the early 1990s (pre-echinocandin era). Our multicenter study included a larger cohort of 2176 candidemia episodes, and showed that currently <6% of these episodes (128 cases) were attributable to the ascending urinary tract source. However, both studies have produced similar findings with regard to the etiology. It seems logical, according to the plausible pathogenesis, that the most common species found were C. albicans and C. glabrata -usual colonizers of the gut and perineum-with C. parapsilosis being a rarer culprit [9] . Remarkably, we found that non-albicans species represented nearly half of cases, and that fluconazole-nonsusceptible strains were isolated in 6% of the cases of CUTS. Finally, Ang et al [10] found an overall mortality of 19%, whereas early and 30-day mortality rates were 6.3% and 14.8%, respectively, in our study. These rates remain high but are lower than those documented in several cohorts of candidemia from all sources (close to 40%) [7, 33] .
Independent prognostic factors in patients with CUTS have not been defined previously. We demonstrated that early drainage of the urinary tract was protective against clinical failure, indicating that a key aspect for the management of CUTS should be the rapid reduction of the Candida species inoculum. In addition, the finding that acute renal failure at onset was an independent predictor of clinical failure is likely an expression of the initial severity of sepsis, and may also be a marker of an unsolved urologic obstructive disorder.
Despite the multicenter design and large number of CUTS episodes analyzed, the main weaknesses of the study are that there is no generally accepted definition of CUTS and that few patients were treated with echinocandins in our cohort. We are aware that the definition we used for CUTS was partly subjective, and that some episodes of endogenous candidemia may, consequently, have been misclassified as CUTS. However, we sought to minimize this bias by using a precise definition that was applied in a uniform manner by specialists experienced in the management of candidemia from a panel of infectious diseases physicians.
In conclusion, our multicenter study of a large cohort of patients with CUTS suggested that initial therapy with echinocandins was not associated with clinical failure. These findings should be confirmed in further studies, particularly those involving larger numbers of patients treated with these drugs. Given the relative rarity of CUTS, a randomized controlled trial is unlikely to be feasible or practical.
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